Mazor Robotics Ltd – (NASDAQ:MZOR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. “
MZOR has been the topic of a number of other reports. Needham & Company LLC reiterated a “hold” rating on shares of Mazor Robotics Ltd – in a research note on Thursday, July 7th. Wells Fargo & Co. upgraded shares of Mazor Robotics Ltd – from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 19th. Barclays PLC increased their price objective on shares of Mazor Robotics Ltd – from $16.00 to $23.00 and gave the company an “overweight” rating in a research note on Thursday, July 14th. Sterne Agee CRT downgraded shares of Mazor Robotics Ltd – from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 31st. Finally, Standpoint Research began coverage on shares of Mazor Robotics Ltd – in a research note on Friday, July 8th. They set a “buy” rating and a $30.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $25.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/mazor-robotics-ltd-mzor-cut-to-hold-at-zacks-investment-research.html
Shares of Mazor Robotics Ltd – (NASDAQ:MZOR) opened at 22.44 on Wednesday. Mazor Robotics Ltd – has a 52 week low of $8.31 and a 52 week high of $24.79. The stock’s market capitalization is $486.34 million. The firm’s 50-day moving average is $22.75 and its 200-day moving average is $16.42.
Mazor Robotics Ltd – (NASDAQ:MZOR) last issued its earnings results on Tuesday, August 2nd. The company reported ($0.09) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.02. The company had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $8.51 million. The business’s revenue was up 6.4% compared to the same quarter last year. During the same period last year, the business posted ($0.05) earnings per share. Analysts forecast that Mazor Robotics Ltd – will post ($0.71) earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in the stock. EAM Investors LLC purchased a new stake in shares of Mazor Robotics Ltd – during the second quarter valued at $2,348,000. Iguana Healthcare Management LLC increased its stake in shares of Mazor Robotics Ltd – by 384.6% in the first quarter. Iguana Healthcare Management LLC now owns 121,151 shares of the company’s stock valued at $1,507,000 after buying an additional 96,151 shares during the period. Menta Capital LLC increased its stake in shares of Mazor Robotics Ltd – by 81.9% in the first quarter. Menta Capital LLC now owns 37,482 shares of the company’s stock valued at $466,000 after buying an additional 16,879 shares during the period. Cookson Peirce & Co. Inc. purchased a new stake in shares of Mazor Robotics Ltd – during the second quarter valued at $192,000. Finally, Candriam Luxembourg S.C.A. purchased a new stake in shares of Mazor Robotics Ltd – during the second quarter valued at $1,079,000.
About Mazor Robotics Ltd –
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Get a free copy of the Zacks research report on Mazor Robotics Ltd – (MZOR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mazor Robotics Ltd – Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mazor Robotics Ltd – and related companies with MarketBeat.com’s FREE daily email newsletter.